Logo

Biogen Reports Mixed Results of Vixotrigine (BIIB074) in P-II CONVEY Study for the Treatment of Small Fiber Neuropathy

Share this

Biogen Reports Mixed Results of Vixotrigine (BIIB074) in P-II CONVEY Study for the Treatment of Small Fiber Neuropathy

Shots:

  • The P-II CONVEY withdrawal study evaluates efficacy & safety of vixotrigine (200/350 mg- bid) vs PBO in 265 patients with SFN for 12wks.
  • The study met its 1EPs i.e.- 200mg dose showed a reduction in mean ADP & worst daily pain score @12wks. while 350mg dose did not meet its 1EPs of mean change in ADP but met statistical significance in PGIC
  • The 2EPs of both doses include a proportion of patients with ≥2-point or improvement in ADP scores with ≥a 30% reduction in ADP @12wks. but the therapy was well-tolerated. The company plan to start a P-III trial based on data from a vixotrigine program

| Ref: Biogen | Image: Biogen

Click here to­ read the full press release 

Senior Editor

This content piece was prepared by our former Senior Editor. She had expertise in life science research and was an avid reader. For any query reach out to us at connect@pharmashots.com

Share this article on WhatsApp, LinkedIn and Twitter

Related News/Articles

Join the PharmaShots family of 12000+ subscribers

I accept the Terms and Conditions